Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Miscellaneous CNS Trials

BTTC 11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The goal of this clinical research study is to learn if Lacosamide can help reduce the risk of seizures in patients with malignant glioma. In this study, Lacosamide will be compared to a placebo. Lacosamide is designed to decrease abnormal electrical activity in the brain that plays a role in developing seizures.

The Brain Tumor Trials Collaborative (BTTC) was created as a network of medical centers with the expertise and the strong desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors. The University of Texas MD Anderson Cancer Center serves as the lead institution and provides the administrative infrastructure, the clinical database and oversight for the collaborative. Twenty two other centers have joined the BTTC. Together with MD Anderson, these institutions will allow patients across a broad geographic range to participate in these cutting-edge clinical trials and more rapidly determine the benefits of these therapies.

Status: Active

Ask a question or refer a patient.

Molecular Biology of Central Nervous System (CNS) Tumors (ARAF: ADM00002083)

Principal Investigator: Pamela New, M.D.
Sub-Investigator: Ching Lau, M.D., Ph.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is to define the biological properties of medulloblastoma and other CNS tumors as well as the genetic alterations leading to the formation of such tumors. Understanding of the biological properties of these tumors will provide clues to new strategies of therapy. Delineation of the genetic changes in the oncogenesis of medulloblastoma and other CNS tumors will result in better prognostic indicators as well as the possibility of early screening and prevention.
Status: Pending

Ask a question or refer a patient.

Identifying prognositc and predictive genomic changes in Meningioma

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The study will provide more definitive assessment of the role of inherited variation in genes influencing both immune function and DNA repair in glioma risk, and therefore help to clarify the role of immunologic factors and radiation exposure in gliomagenesis. Once relevant genes are identified, functional studies can be undertaken to clarify their role.
Status: Active

Ask a question or refer a patient.

BCM GICC: Glioma International Case-Control Study
Principal Investigator: Melissa Bondy, Ph.D.
Sub-Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: By using whole-genome sequencing technology, we will generate preliminary data that will lay the groundwork to understanding specific genomic changes in meningiomas that are associated with either tumor prognosis or response to treatment.
Status: Active

Ask a question or refer a patient.

How Can We Help?
Call us